The ASX200 closed up 0.3% at 8,012 points, just below its all time high set a few weeks ago.
The local bourse climbed higher as both Commonwealth Bank and Macquarie broke share price records.
The Energy sector surged nearly 1%, followed by Telecommunications up 0.8% and IT the same. The Materials sector ended in the red down 1.3%.
In the Green
Paladin Energy (ASX:PDN) closed up more than 6% after Fission shareholders approved a takeover by Paladin. The company says Fission’s Patterson Lake South project is a natural fit. Paladin sees the demand shift for uranium as creating value for its shareholders.
Paladin Energy closed at $8.86.
Metals Australia (ASX:MLS) closed up 5% after kicking off a fresh drilling campaign on the hunt for gold and critical minerals at multiple Australian projects.
Metals Australia closed at 2.1 cents.
Sun Silver (ASX:SS1) has finished up more than 5% after detecting antimony in a historic drill core pulled from its Maverick Springs acreage.
China recently curbed exports of antimony, leading to a run on ASX companies with projects that contain instances of the critical mineral.
Sun Silver pulled up stumps at 62.5 cents.
In the Red
Newly embattled insurance broker Steadfast Group (ASX:SDF) closed down 10.75%, following its inclusion in a Four Corners report overnight.
Reporters behind the broadcast alleged the company has been engaging in anticompetitive behaviour.
The company is alleged to have neglected its obligations to disclose various relationships and the competition regulator has now said it’s looking at regulating the sector more heavily.
Steadfast denies all allegations.
Steadfast closed at $5.32.
Sovereign Metals (ASX:SVM) closed down more than 9% after responding to an ASX price query. The stock went from 68 cents on the 9th of September to a low of 50 cents earlier today. The company says it has no explanation for the recent trading in the securities.
Sovereign Metals closed at 59.5 cents.
Biopharmaceutical play Dimerix (ASX:DXB) closed down 3.7% after the first patient successfully completed the ACTION3 Phase 3 clinical trial. The clinical trial will continue to evaluate safety and efficacy of the treatment.
Dimerix closed at 39 cents.